ePurines, Inc

ePurines is a drug development company specializing in purinergic signaling-based therapeutics. Founded by experts in the field, the company utilizes a technology platform focused on modulating nucleotide P2 receptors and ecto-nucleotidases to address significant health conditions. Its core drug discovery approach incorporates rational drug design, library screening, and artificial intelligence-assisted methodologies. The company holds exclusive licenses for intellectual property from the U.S. Department of Veterans Affairs, covering P2Y2 receptor antagonists for the treatment of lithium-induced nephrogenic diabetes insipidus and diet-induced obesity. Their development strategy emphasizes the creation of orally effective small molecule drugs with improved stability and lower manufacturing costs compared to current injectable market alternatives. These therapies are designed to serve a broad global patient population, including those in emerging and developing markets, with a specific initial focus on addressing unmet medical needs within the Veterans Affairs Healthcare System. By targeting pathways involved in inflammation, metabolism, and organ damage, ePurines aims to provide novel treatment options for patients suffering from obesity, metabolic syndrome, and various renal and liver diseases.